Park Ha Biological Securities Class Action
Analysis based on 89 articles · First reported Jul 28, 2026 · Last updated Aug 23, 2026
The securities class actions against Park Ha Biological Technology Company highlight alleged market manipulation and fraudulent promotion, which could lead to significant financial penalties and reputational damage for the company. The collapse of the stock price and the ensuing litigation may deter investors from similar small-cap IPOs and increase scrutiny on promotional practices in the biotech sector.
Multiple law firms, including Bronstein, Gewirtz & Grossman, Pomerantz, Rosen Law Firm, Levi & Korsinsky (SueWallSt), The Gross Law Firm, and Robbins LLP, have filed or announced securities class actions against Park Ha Biological Technology Company Co., Ltd. (NASDAQ: BYAH, PHH) and certain officers. The lawsuits allege that Park Ha made false and misleading statements during the Class Period from December 27, 2024 to July 8, 2025, failing to disclose a fraudulent stock promotion and market manipulation scheme. According to the complaints, Park Ha's IPO was structured with an extremely low public float, and social media misinformation and impersonated financial professionals artificially inflated the stock price from $4.00 IPO price to an intraday high of $41.49 on July 7, 2025. The stock collapsed approximately 93% on July 8, 2025, closing at $2.99, erasing nearly $1 billion in market capitalization. The lawsuits seek damages for investors who purchased Park Ha securities during the Class Period. Lead plaintiff deadlines are set for September 21 or September 28, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard